Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼± Á¾¾ç¿¡¼­ p53 ¹× ¼¼Æ÷°í»çÀÇ ¹ßÇö¿¡ °üÇÑ ¿¬±¸ The Study of Expression of p53 and Apoptosis in Prostatic Cancer

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 4È£ p.434 ~ 440
±Ç¼º´ë, Á¶ÀçÈï,
¼Ò¼Ó »ó¼¼Á¤º¸
±Ç¼º´ë (  ) 
¾È¾çÁß¾Óº´¿ø ºñ´¢±â°ú

Á¶ÀçÈï (  ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
ÃÖ±Ù ¾Ï¿¬±¸¿¡ À־ ¾Ï¼¼Æ÷ÀÇ »ý¼º, ¼ºÀå µî¿¡ ´ëÇÑ ºÐÀÚ»ý¹°ÇÐÀû ¿¬±¸°¡ È°¹ßÈ÷ ¿¬±¸
µÇ°í ÀÖ´Ù ÀÌÁß ¾Ï¼¼Æ÷ÀÇ À¯ÀüÀÚ ÀÌ»óÀ̶ó´Â Ãø¸éÀ» »ìÆ캸¸é ¾Ï¼¼Æ÷´Â Á¤»ó¼¼Æ÷¿Í ¿©·¯ °¡
Áö »ý¹°ÇÐÀû ¾ç»óÀÇ Â÷À̸¦ ³ªÅ¸³»´Âµ¥, ÀÌ´Â º»ÁúÀûÀ¸·Î ¼¼Æ÷µéÀÇ Ã¼¼¼Æ÷ º¯ÀÌ¿¡ ÀÇÇÑ À¯
ÀüÀÚÀ̻󿡼­ ±âÀÎÇÏ´Â °ÍÀ¸·Î ¹àÇôÁö°Ô µÇ¾ú´Ù. Á¾¾çÀ̶õ °á±¹ ÀÌ·¯ÇÑ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇÑ Á¡
ÁøÀûÀÎ ¼¼Æ÷³»ÀÇ À¯ÀüÀûº¯È­, ¼¼Æ÷Áõ½Ä, Ŭ·ÐÈ®Àå(clonal expansion)ÀÇ ´Ù´Ü°èÀû º¯ÀÌÀÇ °á·Ð
ÀûÀÎ Çö»óÀÌ´Ù. ¾Ï¼¼Æ÷ À¯ÀüÀÚÀÇ µ¹¿¬º¯À̼º º¯È­³ª ¿°»öü ÀÌ»óÀº °¢Á¾ ¾ÏÀ¯ÀüÀÚ ¶Ç´Â p53
°ú °°Àº Á¾¾ç¾ïÁ¦ À¯ÀüÀÚ¿¡ ´ëÇÑ ¿¬±¸·Î½á ±¸Ã¼ÀûÀÎ ÀÌÇØ°¡ °¡´ÉÇØÁö°í ÀÖ´Â ¹Ù, ¾ÏÀÇ ¹ß»ý
Àº ¾Ï À¯ÀüÀÚÀÇ È°¼ºÈ­ ¶Ç´Â Á¾¾ç¾ïÁ¦ À¯ÀüÀÚÀÇ ºñÈ°¼ºÈ­¿¡ ÀÇÇØ À¯¹ßµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁö°í
ÀÖ´Ù.
p53À¯ÀüÀÚ´Â 1979³â óÀ½ ¹ß°ßµÈ ´Ü¹éÁú·Î¼­ Á¤»óÀûÀÎ wild type p53°ú µ¹¿¬º¯ÀÌÇü p53À¸
·Î ±¸ºÐµÇ¸ç ÀÎüÀÇ 17¹ø ¿°»öüÀÇ ´Ü¿Ï(17p)¿¡ À§Ä¡ÇÏ°í ÀÖ´Ù. Á¤»ó p53À¯ÀüÀÚÀÇ ¼¼Æ÷³»
±â´ÉÀº ´Ù¾çÇÏ¿© Àü»çÀÇ È°¼ºÈ­(transcription activation), ¼¼Æ÷ÁÖ±â Á¶Àý, ±×¸®°í ¸¹Àº ´Ù¸¥
´ë»ç±â´Éµé¿¡ °ü¿©ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁö°í ÀÖÀ¸¸ç, ¶ÇÇÑ ¹æ»ç¼±À̳ª È­Çй°Áú¿¡ ÀÇÇØ DNA°¡
¼Õ»óÀ» ¹Þ¾ÒÀ» ¶§ ¿©·¯ ÀÎÀÚµé°ú Çù·ÂÇÏ¿© ¼Õ»óµÈ ¼¼Æ÷ÀÇ ¼ºÀåÀ» Á¤Áö½ÃÅ°°Å³ª ¼ÒÀ§ °èȹÀû
ÀÚ»ì(°í»ç)(programmed cell death, apoptosis)¸¦ À¯¹ß½ÃÄÑ ¾Ï¼¼Æ÷ ÃâÇöÀ» ¹æÁöÇÑ´Ù°í »ý°¢
µÇ°í ÀÖ´Ù. ¶ÇÇÑ µ¹¿¬º¯ÀÌÇü P53ÀÇ ¹ßÇöÀº Á¾¾çÀÇ º´±â¿Í ºÐÈ­µµ¿Íµµ °ü·ÃÀÌ ÀÖÀ¸¸ç Á¾¾çÀÇ
¿¹ÈÄ¿Í´Â ¹ÐÁ¢ÇÑ »ó°ü°ü°è°¡ ÀÖ´Ù´Â °ÍÀÌ ±¹³»¿Ü ³í¹® ´Ù¼ö¿¡¼­ º¸°íµÇ¾î ¿Ô´Ù. °í»ç¿¡ ´ë
ÇÑ ÃÖ±ÙÀÇ ¿¬±¸°á°ú Å»ý±â Àå±âÇü¼º°úÁ¤¿¡ Áß¿äÇÑ ¼¼Æ÷»ç°úÁ¤À̸ç, ¹æ»ç¼±À̳ª È­Çй°Áú·Î
ÀÎÇÑ DNA¼Õ»óÀÌ ÀÖÀ» ¶§ ÀϾ´Â ¼¼Æ÷ÀÇ »ç¸Á±âÀüÀÇ ÇϳªÀÌ´Ù. ƯÁ¤¼¼Æ÷¿¡¼­ p53Àº °í»ç
¸¦ À¯¹ßÇÏ´Â µ¥ ¾Ï À¯ÀüÀÚ¿¡ ÀÇÇؼ­ À¯¹ßµÈ ºñÁ¤»óÀû ¼¼Æ÷Áõ½ÄÀ» p53ÀÌ °í»ç¸¦ À¯¹ßÇÏ¿©
Æı«½ÃÅ´À¸·Î½á ¾Ï¼¼Æ÷ÀÇ ÃâÇöÀ» ¹æÁöÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ°í ÀÖ´Ù.

Purpose : Mutation of the p53 gene in one of the most common genetic abnormalities
found in solid human tumors. p53 gene is related to the cell cycle and concerned with
the control of cellular proliferation or cell death by mediating "programmed cell
death(Apoptosis)". The objective of this study is to evauate the expression of p53
mutations and apoptosis with metastatic prostatic adenocarcinoma.
Materials and Methods : We examined 31 paraffin-embedded tissues and compared
with the tumor grade, survival estimates. Nuclear expression of p53 could be detected
using the monoclonal antibody DO-7 and the expression of apoptosis could be detected
using Apotag by in situ hybridization method. The study group was divided by Gleason
sum score into low score group(score 2-7, 16cases) and high score group(score 8-10,
15cases).
Results : Positive staining for p53 was found in three of sixteen low score
group(19%), eight of fifteen high grade group(53%). Diffuse(>20%) staining was
considered as positive for p53 expression. Positive expression of p53 showed more
frequent in high Gleason score group than low score group(p=0.044). And more
expression for p53 was related to more short survival time than negative p53
group(p=0.041). Mean expression for apoptosis in thirty one cases was 32%. In low
Gleason score group mean expression for apoptosis was 35% and 28% was found in
high Gleason score group. No significant relationship between low and high group in
expressing for apoptosis(p=0.2526). No difference was found for survival time between
two groups(p=0.96). And no specific relationship was found between the expression of
p53 and apoptosis in low and high Gleason score group each other(p=0.275).
Conclusions : p53 mutations play an important role as aggressive biological properties
in the metastatic prostate cancer in relation to Gleason grade. Therefore we might use
the extent of p53 expression as an useful prognostic factor in clinical aspects. But the
expression of apoptosis cannot reveal any specific features with tumor grade, survival
time.

Å°¿öµå

Prostate cancer; p53; Apoptosis; Immunohistochemistry;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS